Egy tanúságtevő hitvalló, szolgáló, tudományos és papi pálya lezárult

Passed a Wittness of the Faith, Scientist, a Servant of The Lord, True Priest: Nicefor Petrashevich (1915–2013), canon of the Preshov Greek Catholic Eparchy. Abstract Decease of the witness of the Faith, a servant of the Lord and a famous researcher of the religious folklore: Nicefor Joseph Petrashevich (1915–2013) distinguished member of the Capitol of Preshov Greek Catholic Eparchy. Born in Čukalovce, East-Slovakia (then Csukalóc, Upper-Hungary) in 1915 as the sixth of the eleven children in the family of a Greek Catholic bishop, he was inspired by his father and elder brother who served the Lord. He studied in the high school (gymnasium) of the Cistercian Order in Eger (Northern Hungary) which provided its pupils with knowledge and deep faith. He became a choir-minister of the Uzghorod Bishopric Basilica where he turned to the examination of folklore traditions reflected in the liturgical chants. Apparently, it was his calling and his findings on the Byzantine chants contributed significantly to the understanding of religious folklore. He was known as a gift ed composer and singer, too. The Greek Catholic Church was banned in the Soviet Union which obtained Subcarpathia after the World War II, and this church was oppressed in Slovakia as well, so he faced a dilemma: to convert to the Ortodox (Pravoslav) Christianity and live free, or to remain faithful to the Catholic Church and be persecuted. Moreover, he was a coelebs, a priest who did not have a wife (despite the fact that Greek Catholic priests are allowed to have families). Consequently, he could have been elected as bishop, as the higher ranks in the Byzantine Churches are open for monks. The communist authorities offered Father Nicefor the episcopate of the Slovak Ortodox Church, if he converted to the Ortodoxy. He refused it: “my head does not accept the mithra (bishops’ crone) by leaving my Catholic faith” –he said. As a result, he was imprisoned for more than two years in Slovakia. Later he came to Hungary where could not serve as a parochial priest, but worked as cantor or helping pope in various places and in centres of pilgrimage where performed the liturgy in Church Slavonic which he sang excellently. Continuing his researches in the folk sings in the liturgy and the local traditions of the liturgical chants, he gained a small grant of the Soros Foundation in 1986 and delivered lectures for two semesters at the Department of the Folklore at the Eötvös University in Budapest in 1988–89. His papers have been partially published, but most of them are still preserved as manuscripts in the Institute of Musicology at the Hungarian Academy of Sciences, or even in unknown places worldwide, as he sent his works to his brothers-in-faith to the United States. In his eighties, instead of enjoying the golden days of ageing, he moved to Slovakia in order to serve as a pastor who spoke both Slovakian and Hungarian as mother tongues. He was buried in Szikszó, Hungary where the Greek Catholic Bishop of Preshov and approximately forty popes from Ukraine, Hungary and Slovakia commemorated him on 20 July 2013. Church historians and folklorists honored his memory as a researcher with a conference on 4 October 2013 in Szikszó. Proceedings are to be published next year. A memorial website about him is open for bloggers

Patient characteristics.

<p>Abbreviations: HR, hormone receptor; IQR, interquartile range; HOMA-IR, homeostasis model assessment for insulin resistance; BMI, body mass index; CTx, chemotherapy; HRT, hormone therapy.</p

Adjusted hazard ratios of PGRN quartile levels for breast cancer recurrence.

<p>Adjusted for age, BMI, tumor size (<2 cm or ≥2 cm), lymph node metastasis (*HR-positive group only), adjuvant chemotherapy (yes or no), adiponectin, HOMA-IR and estradiol.</p><p>Abbreviations: HR, hormone receptor; LN, lymph node; Q, quartile.</p

Characteristics of Patients by Year of Death (n = 696).

<p>Characteristics of Patients by Year of Death (n = 696).</p

The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients

<div><p>Purpose</p><p>This study evaluated the association of serum HER2 (sHER2) levels at diagnosis with clinicopathologic parameters and disease free survival (DFS) in operable breast cancer patients according to intrinsic subtype.</p><p>Methods</p><p>The sHER2 levels were measured using a chemiluminescence immunoassay. The HER2 status in all tumor tissues was determined by immunohistochemistry, and confirmed in equivocal cases by fluorescence in situ.</p><p>Results</p><p>There were 436 consecutive stage I-III breast cancer patients with sHER2 result at diagnosis between Nov 2004 and Dec 2011. High sHER2 levels (≥ 15 ng/ml) were reported in 52 patients (11.9%) and HER2 overexpression in tumor tissue was observed in 111 patients (25.5%). High sHER2 levels were associated significantly with advanced stage (<i>P</i> < 0.001), mastectomy (<i>P</i> = 0.012), neoadjuvant chemotherapy (<i>P</i> < 0.001), anti-HER2 therapy (<i>P</i> < 0.001) and hormone therapy (<i>P</i> = 0.022). The patients with high sHER2 levels had a worse DFS (<i>P</i> < 0.001). In multivariate analysis, high sHER2 levels were associated significantly with worse DFS (HR = 2.25, 95% CI 1.27–3.99, <i>P</i> = 0.005). High sHER2 levels were associated with worse DFS in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes (<i>P</i> = 0.043, 0.003 and 0.041, respectively).</p><p>Conclusions</p><p>These results show that the sHER2 level at diagnosis is a useful prognostic factor in patients with operable breast cancer, especially in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes.</p></div

Trends for administering new chemotherapy as aggressive end-of-life care to Korean pediatric cancer patients who died 2007–2010.

<p>Trends for administering new chemotherapy as aggressive end-of-life care to Korean pediatric cancer patients who died 2007–2010.</p

Relationship between serum HER2 levels and clinicopathologic characteristics.

<p>Relationship between serum HER2 levels and clinicopathologic characteristics.</p

Multivariate analysis for disease free survival.

<p>Multivariate analysis for disease free survival.</p

Trends in Indicators of Aggressive Care during the 4-Year Study Period (n = 696).

<p>Trends in Indicators of Aggressive Care during the 4-Year Study Period (n = 696).</p

Intrinsic subtype specific disease free survival according to serum HER2 levels.

<p>(A) HR+/HER2- subtype; (B) HR+/HER2+ subtype; (C) HR-/HER2+ subtypes; (D) HR-/HER2- subtypes. sHER2 = serum HER2 levels; NA = not available.</p